Pyruvate Dehydrogenase Kinase 3 (PDK3) is an integral enzyme involved in the regulation of the mitochondrial pyruvate dehydrogenase complex (PDC), which plays a pivotal role in the metabolic pathway linking glycolysis to the citric acid cycle. PDK3 functions by phosphorylating and thereby inactivating the E1 subunit of the PDC, effectively downregulating the conversion of pyruvate to acetyl-CoA, a critical step in cellular energy production. This regulation allows the cell to adapt its energy metabolism in response to changes in nutrient availability and energy demands, shifting between glycolysis and oxidative phosphorylation as necessary. The activity of PDK3 is crucial for maintaining metabolic flexibility, enabling cells to efficiently manage energy production and consumption under various physiological conditions, including periods of fasting, exercise, or altered dietary intake.
The activation of PDK3 involves a complex interplay of cellular signals and conditions that reflect the metabolic state of the cell. It is regulated by a variety of factors, including the availability of substrates and allosteric effectors, such as ATP, NADH, and acetyl-CoA, which signal high energy levels and decrease PDC activity through PDK3 activation. Conversely, an abundance of pyruvate or ADP can signal a need for increased ATP production, leading to the inhibition of PDK3 and activation of the PDC. Additionally, hormonal signals, particularly insulin, can influence PDK3 activity, linking it to broader metabolic control mechanisms. Insulin promotes the dephosphorylation and activation of the PDC, indirectly modulating PDK3 activity to favor glucose oxidation. The regulation of PDK3 thus represents a critical nodal point in cellular metabolism, integrating various signals to modulate energy production pathways according to the cell's immediate and long-term energetic and biosynthetic requirements. Understanding the mechanisms of PDK3 activation and its role in metabolic regulation provides insight into cellular energy management and the adaptation to metabolic stress.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $236.00 $987.00 | 5 | |
UK5099 is an inhibitor of the mitochondrial pyruvate carrier (MPC), indirectly affecting PDK3 by limiting pyruvate entry into the mitochondria. By inhibiting MPC, UK5099 reduces mitochondrial pyruvate levels, resulting in decreased substrate availability for PDK3. This limitation on pyruvate availability can alleviate PDK3-mediated inhibition of PDH, promoting enhanced pyruvate metabolism. The indirect modulation of PDK3 by UK5099 through MPC inhibition sheds light on the intricate regulation of mitochondrial pyruvate transport and its impact on PDK activity. | ||||||
Sodium dichloroacetate | 2156-56-1 | sc-203275 sc-203275A | 10 g 50 g | $55.00 $209.00 | 6 | |
NaDCA is the sodium salt form of DCA, acting similarly by indirectly inhibiting PDK3. It promotes PDH activity, leading to increased conversion of pyruvate to acetyl-CoA. This indirect inhibition of PDK3 by NaDCA highlights its potential as a modulator of pyruvate metabolism and a tool for investigating the role of PDK3 in cellular processes. | ||||||
1,3-Dichloroacetone | 534-07-6 | sc-237720 | 10 g | $42.00 | ||
1,3-Dichloroacetone is a metabolite of DCA and acts similarly by indirectly inhibiting PDK3. It stimulates PDH activity, leading to increased conversion of pyruvate to acetyl-CoA. The indirect inhibition of PDK3 by DCAc reflects its role as a downstream effector in the modulation of pyruvate metabolism. | ||||||
BAY 87-2243 | 1227158-85-1 | sc-507483 | 5 mg | $100.00 | ||
BAY 87-2243 is a pyruvate mimetic that indirectly affects PDK3 by promoting PDH activity. By mimicking the structure of pyruvate, BAY 87-2243 enhances PDH activity, reducing the substrate available for PDK3. This indirect modulation of PDK3 by BAY 87-2243 provides a pharmacological tool for investigating the role of PDK3 in cellular processes and the potential therapeutic implications of targeting pyruvate metabolism. | ||||||
2,3-Dihydroxy-6-methyl-7-(phenylmethyl)-4-propyl-1-naphthalenecarboxylic Acid | 213971-34-7 | sc-498807 | 1 mg | $480.00 | ||
This compound, also called FX11, is a lactate dehydrogenase (LDH) inhibitor that indirectly influences PDK3 by disrupting lactate production. Inhibition of LDH by FX11 reduces the conversion of pyruvate to lactate, leading to increased availability of pyruvate for metabolic pathways, potentially including PDK3-mediated inhibition of PDH. | ||||||